Readystate Asset Management LP Increases Stock Position in Enfusion, Inc. (NYSE:ENFN)

Readystate Asset Management LP grew its stake in Enfusion, Inc. (NYSE:ENFN - Free Report) by 173.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 109,243 shares of the company's stock after purchasing an additional 69,328 shares during the quarter. Readystate Asset Management LP owned about 0.09% of Enfusion worth $1,037,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ENFN. RiverPark Advisors LLC bought a new position in Enfusion in the 2nd quarter worth $68,000. Arizona State Retirement System purchased a new stake in shares of Enfusion in the 2nd quarter worth about $86,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Enfusion in the 1st quarter worth about $102,000. Harbor Capital Advisors Inc. grew its position in shares of Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock worth $113,000 after buying an additional 1,315 shares during the period. Finally, Belvedere Trading LLC purchased a new stake in shares of Enfusion in the 3rd quarter worth about $114,000. 81.05% of the stock is currently owned by institutional investors.

Enfusion Stock Down 1.0 %

Shares of NYSE:ENFN traded down $0.10 during midday trading on Thursday, reaching $10.01. The company's stock had a trading volume of 68,527 shares, compared to its average volume of 381,777. The firm has a 50 day moving average of $9.36 and a 200-day moving average of $8.90. The firm has a market capitalization of $1.29 billion, a P/E ratio of 252.81, a PEG ratio of 3.79 and a beta of 0.97. Enfusion, Inc. has a 12-month low of $7.52 and a 12-month high of $10.40.

Insider Transactions at Enfusion

In related news, COO Neal Pawar sold 21,801 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the sale, the chief operating officer now directly owns 1,143,544 shares of the company's stock, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 36.44% of the company's stock.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.